Macimorelin Explained

Tradename:Macrilen
Dailymedid:Macimorelin
Routes Of Administration:By mouth
Atc Prefix:V04
Atc Suffix:CD06
Legal Us:Rx-only
Legal Eu:Rx-only
Legal Eu Comment:[1] [2]
Metabolism:Hepatic (CYP3A4-mediated)
Elimination Half-Life:4.1 hours
Index2 Label:as salt
Cas Number:381231-18-1
Cas Supplemental:945212-59-9 (acetate)
Pubchem:9804938
Drugbank:DB13074
Chemspiderid:7980698
Unii:8680B21W73
Kegg:D10563
Kegg2:D10562
Chembl:278623
Synonyms:Aib-Trp-gTrp-CHO; AEZS-130; JMV 1843; Macimorelin acetate
Iupac Name:2-Amino-N-[(2''R'')-1-[[(1''R'')-1-formamido-2-(1''H''-indol-3-yl)ethyl]amino]-3-1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide
C:26
H:30
N:6
O:3
Smiles:CC(C)(C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)NC=O)N
Stdinchi:1S/C26H30N6O3/c1-26(2,27)25(35)31-22(11-16-13-28-20-9-5-3-7-18(16)20)24(34)32-23(30-15-33)12-17-14-29-21-10-6-4-8-19(17)21/h3-10,13-15,22-23,28-29H,11-12,27H2,1-2H3,(H,30,33)(H,31,35)(H,32,34)/t22-,23-/m1/s1
Stdinchikey:UJVDJAPJQWZRFR-DHIUTWEWSA-N

Macimorelin (INN) – or Macrilen (trade name) – is a drug that was developed by Aeterna Zentaris for use in the diagnosis of adult growth hormone deficiency.[3] Macimorelin acetate, the salt formulation, is a synthetic growth hormone secretagogue receptor agonist.[4] It is a growth hormone secretagogue receptor (ghrelin receptor) agonist, causing release of growth hormone from the pituitary gland.[5] [6] [7] Macimorelin acetate is described chemically as D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-acetate.

Macimorelin (Macrilen) was invented and first synthesized at University of Montpellier, Centre National de la Recherche Scientitifique (CNRS), France.[8] [9] [10] This transpired from a long-lasting research collaboration with Aeterna Zentaris. Aeterna Zentaris later in-licensed macimorelin as a development candidate from the CNRS and proceeded with the pre-clinical and clinical development of the compound.

As of January 2014, it was in Phase III clinical trials.[11] The phase III trial for growth hormone deficiency is expected to be complete in December 2016.

As of December 2017, it was FDA-approved as a method to diagnose growth hormone deficiency.[12] [13] Traditionally, growth hormone deficiency was diagnosed via means of insulin tolerance test (IST) or glucagon stimulation test (GST). These two means are done parenterally, whereas Macrilen boasts an oral formulation for ease of administration for patients and providers.

The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[14]

See also

Notes and References

  1. Web site: Macimorelin Aeterna Zentaris . European Medicines Agency (EMA) . 13 November 2018 . 28 September 2020.
  2. Web site: Ghryvelin (previously Macimorelin Aeterna Zentaris) . European Medicines Agency . 26 February 2019 . 15 May 2024.
  3. Web site: Macimorelin Aeterna Zentaris. www.ema.europa.eu. 13 November 2018 .
  4. Web site: Macrilen Prescribing Information. 2018-07-25.
  5. Web site: Macimorelin. NCI Drug Dictionary. National Cancer Institute.
  6. Koch L . Growth hormone in health and disease: Novel ghrelin mimetic is safe and effective as a GH stimulation test . Nature Reviews. Endocrinology . 9 . 6 . 315 . June 2013 . 23591367 . 10.1038/nrendo.2013.89 . 10475359 . free .
  7. Garcia JM, Swerdloff R, Wang C, Kyle M, Kipnes M, Biller BM, Cook D, Yuen KC, Bonert V, Dobs A, Molitch ME, Merriam GR . 6 . Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency . The Journal of Clinical Endocrinology and Metabolism . 98 . 6 . 2422–2429 . June 2013 . 23559086 . 4207947 . 10.1210/jc.2013-1157 .
  8. Growth hormone secretagogues. Martinez J, Fehrentz JA, Guerlavais V . WO. 2001096300. 20 December 2001 . Zentaris AG .
  9. Broglio F, Boutignon F, Benso A, Gottero C, Prodam F, Arvat E, Ghè C, Catapano F, Torsello A, Locatelli V, Muccioli G, Boeglin D, Guerlavais V, Fehrentz JA, Martinez J, Ghigo E, Deghenghi R . 6 . EP1572: a novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man . Journal of Endocrinological Investigation . 25 . 8 . RC26–RC28 . September 2002 . 12240910 . 10.1007/BF03345096 . 25962252 .
  10. Guerlavais V, Boeglin D, Mousseaux D, Oiry C, Heitz A, Deghenghi R, Locatelli V, Torsello A, Ghé C, Catapano F, Muccioli G, Galleyrand JC, Fehrentz JA, Martinez J . 6 . New active series of growth hormone secretagogues . Journal of Medicinal Chemistry . 46 . 7 . 1191–1203 . March 2003 . 12646029 . 10.1021/jm020985q .
  11. News: Aeterna Zentaris NDA for Macimorelin Acetate in AGHD Accepted for Filing by the FDA . The Wall Street Journal . January 6, 2014.
  12. Web site: Drug Approvals and Databases - Drug Trials Snapshots: Marcrilen . www.fda.gov. 2018-07-25.
  13. Web site: FDA Approves Aeterna Zentaris' Macimorelin Growth Hormone Deficiency Test. 2021-07-04. HCPLive. 21 December 2017 .
  14. New Drug Therapy Approvals 2017 . U.S. Food and Drug Administration (FDA) . January 2018 . PDF . 16 September 2020.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Macimorelin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.